Our understanding of the role of potential biomarkers (LEP, NGF and PCOLCE2) in COAD is still limited, and further research is essential to investigate the effects on other COAD cell lines and tumors derived from COAD patients to enhance the validity of the findings. This evidence concerns the gene LEP and colon adenocarcinoma.